1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>South Korea

What Can Korea Learn From The Invossa Trial And Error Case?

 
• By Jung Won Shin

South Korea, which has recently delayed the political passage of a cutting-edge regenerative medicine and biologics act, should learn from the latest unprecedented incident involving Kolon Life Science’s cell and gene therapy Invossa, and pre-emptively make preparations and guidelines to better deal with such pioneering medicines, an industry expert tells Scrip.

TrialandError
Korea Should Take Preemptive Moves In Learning From Invossa Incident • Source: Shutterstock

Trial and error is frequently, if not always, an accompaniment to the introduction of new technologies. As one example, in South Korea there was huge controversy a decade ago relating to a stem cell research scandal involving a local cloning scientist.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Asia